60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Rhea-AI Summary

60 Degrees Pharmaceuticals (NASDAQ: SXTP) will effect a one-for-four (1:4) reverse stock split of its common stock, effective January 20, 2026 at 12:01 AM ET, before market open. The company said the reverse split is intended to bring SXTP into compliance with Nasdaq's minimum bid price requirement. The reverse split will change the CUSIP to 83006G500, reduce outstanding shares from approximately 5,148,767 to approximately 1,287,192, and adjust all outstanding options, warrants, restricted stock awards and equity plan share counts. Par value and authorized share totals remain unchanged. Fractional shares will be rounded up to the next whole share.

Positive

• Aims to regain Nasdaq compliance with minimum bid price requirement
• Outstanding shares reduced from ~5,148,767 to ~1,287,192 (1:4 ratio)

Negative

• All outstanding options, warrants and restricted awards will be adjusted due to the reverse split
• Equity incentive plan share counts will be reduced and adjusted by the reverse split

News Market Reaction

-2.39% 8.9x vol

19 alerts

-2.39% News Effect

+70.7% Peak in 32 hr 21 min

-$65K Valuation Impact

$3M Market Cap

8.9x Rel. Volume

On the day this news was published, SXTP declined 2.39%, reflecting a moderate negative market reaction. Argus tracked a peak move of +70.7% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $65K from the company's valuation, bringing the market cap to $3M at that time. Trading volume was exceptionally heavy at 8.9x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Reverse split ratio: 1-for-4 Effective date: January 20, 2026 Par value: $0.0001 per share +2 more

5 metrics

Reverse split ratio 1-for-4 Approved reverse stock split of common stock

Effective date January 20, 2026 Reverse split effective at 12:01 AM Eastern

Par value $0.0001 per share Par value of common stock unchanged post-split

Shares outstanding pre-split 5,148,767 shares Approximate common shares before 1-for-4 split

Shares outstanding post-split 1,287,192 shares Approximate common shares after 1-for-4 split

Market Reality Check

Price: $4.82 Vol: Volume 688,040 is 2.27x t...

high vol

$4.82 Last Close

Volume Volume 688,040 is 2.27x the 20-day average of 303,559 ahead of the reverse split announcement. high

Technical Shares trade below the 200-day MA of 1.67 and are 92.05% under the 52-week high of 6.00.

Peers on Argus

SXTP was down 9.57% while peers were mixed: TTNP -3.96%, KTTA -1.12%, ARTL +1.90...

SXTP was down 9.57% while peers were mixed: TTNP -3.96%, KTTA -1.12%, ARTL +1.90%, PLRZ +6.41%, SILO +1.75%, suggesting a stock-specific move tied to the reverse split.

Historical Context

5 past events · Latest: Dec 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 29	Clinical study data	Positive	-20.6%	Study found Babesia infection in 24% of 50 chronic fatigue patients.
Dec 11	Commercial update	Positive	-7.0%	Planned 2026 ARAKODA sales expansion and added babesiosis clinical sites.
Nov 21	Trial enrollment	Positive	+0.0%	B-FREE Phase 2 babesiosis study opened for enrollment at Mount Sinai.
Nov 13	Q3 2025 earnings	Negative	-5.4%	Q3 showed higher revenue but gross loss and net loss per share.
Oct 15	Clinical update	Positive	-14.2%	First expanded-access patient tested negative for Babesia after tafenoquine.

Pattern Detected

Recent operational and clinical updates with generally positive tone have often been followed by flat or negative price reactions, while the one clearly negative-leaning earnings update aligned with a price decline.

Recent Company History

Over the past few months, 60 Degrees Pharmaceuticals has focused on babesiosis programs and ARAKODA commercialization. Key steps included opening the B-FREE Phase 2 site at Mount Sinai, reporting Babesia detection in 24% of chronic fatigue patients, and outlining 2026 sales and marketing expansion. Q3 2025 results showed sharply higher net product revenue but a continued net loss. Despite these clinical and commercial milestones, several updates around babesiosis and regulatory interactions were followed by flat or negative price moves, providing context for how investors have reacted to prior corporate events.

Market Pulse Summary

This announcement details a 1-for-4 reverse stock split effective January 20, 2026, reducing outstan...

Analysis

This announcement details a 1-for-4 reverse stock split effective January 20, 2026, reducing outstanding common shares from roughly 5,148,767 to 1,287,192 while keeping par value and authorized share counts unchanged. The primary goal is Nasdaq minimum bid-price compliance. Investors may track how this fits alongside recent clinical and commercial milestones, overall cash needs, and whether future corporate actions further affect capital structure and listing status.

Key Terms

reverse stock split, cusip, equity incentive plan, warrants

4 terms

reverse stock split financial

"announced that it will effect a one-for-four (1:4) reverse stock split"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

cusip financial

"The new CUSIP number for the Common Stock following the reverse split"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

equity incentive plan financial

"The number of shares available to be awarded under any Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

warrants financial

"All outstanding options, restricted stock awards, warrants and other securities"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

AI-generated analysis. Not financial advice.

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "SXTP".

The reverse split is primarily intended to bring 60 Degrees Pharma into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq. The new CUSIP number for the Common Stock following the reverse split will be 83006G500.

At 60 Degree Pharma’s special meeting of stockholders on October 8, 2025 (the "Special Meeting"), 60 Degree Pharma’s stockholders approved the proposal to authorize 60 Degree Pharma’s board of directors (the "Board"), in its sole and absolute discretion, to file a certificate of amendment (the "Amendment") to 60 Degree Pharma’s amended and restated certificate of incorporation to effect the reverse split of the Company at a ratio of one-to-four (1:4). On December 17, 2025, the Board approved the reverse split at a ratio of one-to-four (1:4), and the Amendment has been filed with the Secretary of State of the State of Delaware, which will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on Nasdaq.

The reverse split will affect all issued and outstanding shares of Common Stock. All outstanding options, restricted stock awards, warrants and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under any Equity Incentive Plan, will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 per share. The reverse split will not change the authorized number of shares of Common Stock or preferred stock. No fractional shares of Common Stock shall be issued as a result of the Reverse Split, and stockholders who otherwise would be entitled to receive fractional shares of New Common Stock shall be entitled to receive the number of shares of New Common Stock rounded up to the next whole number. The reverse split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in 60 Degree Pharma’s equity (other than as a result of the rounding of fractional shares, as set forth above).

The reverse split will reduce the number of shares of Common Stock issued and outstanding from approximately 5,148,767 to approximately 1,287,192.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of Its lead product, ARAKODA^® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research and academic organizations in the U.S. and Australia. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA^® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward- looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com

Source: Sixty Degrees Pharmaceuticals

FAQ

What reverse split did 60 Degrees Pharmaceuticals (SXTP) approve and when does it take effect?

SXTP approved a one-for-four (1:4) reverse split effective January 20, 2026 at 12:01 AM ET before Nasdaq opens.

How many SXTP shares will be outstanding after the 1:4 reverse split?

Outstanding shares will be reduced to approximately 1,287,192 from about 5,148,767.

Will 60 Degrees Pharmaceuticals (SXTP) keep the same ticker after the reverse split?

Yes, SXTP requested that its common stock continue trading under the existing symbol SXTP on a post-reverse split basis.

What happens to options, warrants and restricted stock when SXTP executes the reverse split?

All outstanding options, warrants and restricted stock awards will be adjusted as required by their terms to reflect the 1:4 reverse split.

Will the reverse split change SXTP's authorized shares or par value?

No; the reverse split will not change the authorized number of common or preferred shares and par value remains $0.0001 per share.

How will fractional SXTP shares be handled after the reverse split?

No fractional shares will be issued; holders entitled to fractions will receive the number of new shares rounded up to the next whole share.